CTNM - Contineum Therapeutics, Inc. News

RBC Capital Maintains Outperform on Contineum Therapeutics, Raises Price Target to $23

RBC Capital analyst Brian Abrahams maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperfo

Contineum Therapeutics Implements Workforce Reduction For Its Research Team Including Chief Scientif

Contineum has streamlined its discovery programs to focus on drug candidates for the treatment of in

Contineum Therapeutics Q2 EPS $(0.40) Beats $(0.48) Estimate

Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.40) per share which beat the a

Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Developme

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),

Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice

Does Contineum Therapeutics, Inc. (CTNM) have what it takes to be a top stock pick for momentum inve

gurufocus.com

Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in J

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmace

Contineum Therapeutics Publishes 'Discovery of PIPE-791, a Potent and Brain-Penetrant Lysophosphatid

- Manuscript describes the discovery of LPAR1 antagonist PIPE-791, now in a Phase 2 clinical trial f

Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in J

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),

Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),

Wall Street Analysts See a 59.96% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Reall

The consensus price target hints at a 60% upside potential for Contineum Therapeutics, Inc. (CTNM).

marketbeat.com

Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential

Contineum Therapeutics NASDAQ: CTNM President and Chief Executive Officer Carmine Stengone said the

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),

Morgan Stanley Maintains Equal-Weight on Contineum Therapeutics, Raises Price Target to $16

Morgan Stanley analyst Jeffrey Hung maintains Contineum Therapeutics (NASDAQ:CTNM) with a Equal-W

Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),

Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 In

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),

Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 49.21%: Read This Before

The average of price targets set by Wall Street analysts indicates a potential upside of 49.2% in Co

Contineum Therapeutics Q1 EPS $(0.39) Beats $(0.51) Estimate

Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.39) per share which beat the a

Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Developmen

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),

Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),

Contineum Therapeutics Stock Edges Higher As PIPE-791 Pain Data Clears Safety Bar

Contineum stock rises after PIPE-791 pain trial shows safety and early efficacy signals, with mixed

Contineum Therapeutics Announces Its Phase 1b Study Of PIPE-791 Meets Primary Endpoint By Demonstrat

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmace

Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),

defenseworld.net

Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Consensus Rating of “Moderate Buy” from Analysts

Contineum Therapeutics, Inc. (NASDAQ: CTNM - Get Free Report) has been given a consensus recommendat

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),

Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Developme

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),

Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),

Is Contineum Therapeutics, Inc. (CTNM) Stock Outpacing Its Medical Peers This Year?

Here is how Contineum Therapeutics, Inc. (CTNM) and Quest Diagnostics (DGX) have performed compared

Moderna, Kosmos Energy, Option Care Health, Kennametal And Other Big Stocks Moving Higher On Tuesday